+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review

MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type-2 diabetes. It consists of a dry powder formulation of human insulin delivered from small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. Mannkind has manufacturing facility in Danbury, Connecticut and sells product to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.

MannKind Corp Key Recent Developments

  • May 24, 2023: Dr. Burkhard Blank joins MannKind as executive vice president of research & development and chief medical officer
  • May 09, 2023: Mannkind reports 2023 first quarter financial results
  • May 02, 2023: MannKind Corp. to hold 2023 first quarter financial results conference call on May 9, 2023
  • Mar 27, 2023: Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • MannKind Corp - Key Facts
  • MannKind Corp - Key Employees
  • MannKind Corp - Key Employee Biographies
  • MannKind Corp - Major Products and Services
  • MannKind Corp - History
  • MannKind Corp - Company Statement
  • MannKind Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • MannKind Corp - Business Description
  • Business Segment: Collaborations and Services
  • Overview
  • Performance
  • Business Segment: Commercial Product Sales
  • Overview
  • Performance
  • Business Segment: Royalties- collaborations
  • Performance
  • R&D Overview
  • MannKind Corp - Corporate Strategy
  • MannKind Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • MannKind Corp - Strengths
  • MannKind Corp - Weaknesses
  • MannKind Corp - Opportunities
  • MannKind Corp - Threats
  • MannKind Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • MannKind Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 24, 2023: Dr. Burkhard Blank joins MannKind as executive vice president of research & development and chief medical officer
  • May 09, 2023: Mannkind reports 2023 first quarter financial results
  • May 02, 2023: MannKind Corp. to hold 2023 first quarter financial results conference call on May 9, 2023
  • Mar 27, 2023: Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
  • Feb 23, 2023: MannKind Corp. Reports 2022 Fourth Quarter and Full Year Financial Results
  • Feb 16, 2023: MannKind Corp. to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
  • Jan 24, 2023: MannKind to Participate in the Lytham Partners Investor Select Conference
  • Nov 08, 2022: MannKind Reports 2022 Third Quarter Financial Results
  • Sep 21, 2022: MannKind to Participate in the Lytham Partners Fall 2022 Investor Conference
  • Aug 09, 2022: MannKind Corp Reports 2022 Second Quarter Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • MannKind Corp, Key Facts
  • MannKind Corp, Key Employees
  • MannKind Corp, Key Employee Biographies
  • MannKind Corp, Major Products and Services
  • MannKind Corp, History
  • MannKind Corp, Other Locations
  • MannKind Corp, Subsidiaries
  • MannKind Corp, Key Competitors
  • MannKind Corp, Ratios based on current share price
  • MannKind Corp, Annual Ratios
  • MannKind Corp, Interim Ratios
  • MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • MannKind Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • MannKind Corp, Performance Chart (2018 - 2022)
  • MannKind Corp, Ratio Charts
  • MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Novo Nordisk AS
  • Eli Lilly and Co
  • Aerami Therapeutics Inc
  • Sanofi
  • Pfizer Inc
  • Sanofi
  • Pfizer Inc
  • Novo Nordisk AS
  • Eli Lilly and Co
  • Aerami Therapeutics Inc